News

Posit Science, YMCA Team Up for Dementia Prevention Program

Posit Science, which produces the BrainHQ app, is collaborating with the YMCA of San Francisco to establish a model community-based program for dementia prevention. Posit Science received a $465,000 grant from the National Institutes of Health to develop the program with the YMCA and input from brain health experts at…

Most Women Unaware of Alzheimer’s Risk, Survey Finds

Women in the United States are largely uninformed when it comes to some critical health issues, including their relatively higher risk of developing Alzheimer’s disease as compared to men, according to a comprehensive survey about the state of women’s health. Results of the survey conducted by the Women’s Alzheimer’s Movement…

ALPHA-1062 May Be Substitute for Razadyne: Bioequivalence Study

ALPHA-1062, Alpha Cognition’s investigational oral tablet for mild to moderate Alzheimer’s disease, may be a bioequivalent substitute for the approved therapy Razadyne, according to a pivotal trial with healthy volunteers. The pro-drug therapy — meaning that the medication is metabolized in the body, after administration — showed positive…

New VirtuALZ Program Aims to Offer Caregiver Support

Caring for a loved one with Alzheimer’s disease (AD) can be overwhelming. To help ease the caregiver burden — and ultimately benefit patients — a Florida-based company called VirtuALZ is offering a new virtual support program. Crafted specifically to support caregivers of patients who have Alzheimer’s and related…

Brain Health Academy Will Offer Wellness Guidance to Professionals

UsAgainstAlzheimer’s is preparing to launch free online courses — The Brain Health Academy — teaching health and wellness professionals how to help people reduce the risk of Alzheimer’s and dementia. Developed in partnership with the American Heart Association, The American College of Lifestyle Medicine, and the Centers for…

Tau-targeting Treatment Slows Cognitive, Functional Declines: Trial

Alzheimer’s patients given the experimental tau-targeting therapy HMTM in a Phase 3 clinical trial experienced a substantially slower decline in cognitive and functional measures than would be expected based on published research, according to new findings announced by HMTM’s developer TauRx Pharmaceuticals. TauRx expects these results will…

New Community-driven Model Aims to Improve Alzheimer’s Screening

An innovative new project in Toronto will combine optometry and community-based cognitive testing to improve Alzheimer’s screening and enable the early detection of the progressive neurodegenerative disorder. The project — launching in Ontario, Canada — will be led by the medical imaging company RetiSpec and the community-based medical center…